Evidence map›Paper›PMID 36428378›Full record

ArticleAnimals : an open access journal from MDPI2022

Brain Organoids to Evaluate Cellular Therapies.

Ana Belén García-Delgado, Rafael Campos-Cuerva, Cristina Rosell-Valle, María Martin-López, Carlos Casado, Daniela Ferrari, Javier Márquez-Rivas, Rosario Sánchez-Pernaute, Beatriz Fernández-Muñoz

Open access · goldAbstract read
In one paragraph

Article in Animals : an open access journal from MDPI, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ana Belén García-DelgadoUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.
Rafael Campos-CuervaUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.ORCID 0000-0002-4731-1055
Cristina Rosell-ValleUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.ORCID 0000-0001-9545-0976
María Martin-LópezUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.ORCID 0000-0002-3255-6367
Carlos CasadoUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.
Daniela FerrariDepartment of Biotechnology and Biosciences, University Milan-Bicocca, 20126 Milan, Italy.ORCID 0000-0001-7251-9854
Javier Márquez-RivasIBiS, Instituto de Biomedicina de Sevilla, 41013 Sevilla, Spain.ORCID 0000-0002-5136-4723
Rosario Sánchez-PernauteUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.ORCID 0000-0003-1144-9025
Beatriz Fernández-MuñozUnidad de Producción y Reprogramación Celular (UPRC), Red Andaluza de Diseño y Traslación de Terapias Avanzadas (RAdytTA), Fundación Progreso y Salud, 41092 Sevilla, Spain.ORCID 0000-0003-4238-9598
Fundación Progreso y Salud · ESInstituto de Biomedicina de Sevilla · ESUniversity of Milano-Bicocca · IT

Funding

Fundación Alicia Koplowitz 1620480AKPWInstituto de Salud Carlos III DTS20/00108Instituto de Salud Carlos III PT20/00065
6 · The paper itself

Abstract

Animal models currently used to test the efficacy and safety of cell therapies, mainly murine models, have limitations as molecular, cellular, and physiological mechanisms are often inherently different between species, especially in the brain. Therefore, for clinical translation of cell-based medicinal products, the development of alternative models based on human neural cells may be crucial. We have developed an in vitro model of transplantation into human brain organoids to study the potential of neural stem cells as cell therapeutics and compared these data with standard xenograft studies in the brain of immunodeficient NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice. Neural stem cells showed similar differentiation and proliferation potentials in both human brain organoids and mouse brains. Our results suggest that brain organoids can be informative in the evaluation of cell therapies, helping to reduce the number of animals used for regulatory studies.

Indexed as

3 Rsbrain organoidscell therapyneural progenitorsneural stem cellsreductiontranslation

Identifiers

PMID36428378
PMCPMC9686900
OpenAlexW4309314690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.